LTD.;默里和普尔企业有限公司;MURRAY & POOLE ENTERPRISES, LTD.;MURRAY & POOLE ENTERPRISES;默里和普爾企業有限公司
发明人:
NIDORF, Mark,马克．尼杜夫,馬克．尼杜夫,马克.尼杜夫,馬克.尼杜夫
申请号：
MOJ003172
公开号：
MOJ003172B
申请日:
2018.07.06
申请国别(地区):
MO
年份:
2018
代理人:
摘要：
The method for treating or preventing the cardiovascular event in the individual with atherosclerotic blood vessel disease,Itself the following steps are included: b) give the compound of the logical formula (I) of therapeutically effective amount,Known colchicine derivative and/or its salt,Wherein: R1,R2,R3,R4,R9,R10,R11 and R12 independently indicate hydrogen,C1-4 alkyl,C2-4 alkenyl,C3-6 naphthenic base,Halogen,C1-4 halogenated alkyl,Nitro,Amino,C2-4 acyl amino,C1-4 alkyl or dialkyl amido,Hydroxyl,C1-4 alkoxy,C1-4 alkylthio,The group of general formula-SO2N (Rx) 2 or SO2Rx wherein Rx be C1-4 alkyl,C1-4 acyloxy or the phenyl optionally replaced,The phenoxy group optionally replaced； R7 and R8 independently indicate hydrogen,C1-4 alkyl or C1-4 acyl group； And R5 ',R5”,R6 ' and R6 " independently indicate hydrogen,C1-4 alkyl,C2-4 alkenyl,C3-6 naphthenic base,Halogen,C1-4 halogenated alkyl,Nitro,Amino,C2-4 acyl amino,Hydroxyl,C1-4 alkoxy or C1-4 alkylthio,The group of general formula-SO2N (Rx) 2 or SO2Rx wherein Rx be C1-4 alkyl,C1-4 acyloxy or the phenyl optionally replaced.治療或預防患有動脉粥樣硬化血管疾病的個體中的心血管事件的方法，其包括以下步驟：b)給予治療有效量的通式(I)的化合物、已知的秋水仙碱衍生物和／或其鹽，其中：R1、R2、R3、R4、R9、R10、R11和R12獨立地表示氫、C1‑4烷基、C2‑4烯基、C3‑6環烷基、鹵素、C1‑4鹵代烷基、硝基、氨基、C2‑4酰基氨基、C1‑4烷基或二烷基氨基、羥基、C1‑4烷氧基、C1‑4烷基硫代、通式‑SO2N(Rx)2或SO2Rx的基團其中Rx爲C1‑4烷基、C1‑4酰氧基或任選取代的苯基、任選取代的苯氧基；R7和R8獨立地表示氫、C1‑4烷基或C1‑4酰基；且R5’、R5”、R6’和R6”獨立地表示氫、C1‑4烷基、C2‑4烯基、C3‑6環烷基、鹵素、C1‑4鹵代烷基、硝基、氨基、C2‑4酰基氨基、羥基、C1‑4烷氧基或C1‑4烷基硫代、通式‑SO2N(Rx)2或SO2Rx的基團其中Rx爲C1‑4烷基、C1‑4酰氧基或任選取代的苯基。
